title: Plasma adiponectin concentration before and after successful kidney transplantation.
abstract: BACKGROUND
  Adiponectin, a protein secreted exclusively by adipocytes, is presumed to be involved in the pathogenesis of atherosclerosis and insulin resistance. An elevated plasma adiponectin concentration was found in ESRD patients on hemodialysis (HD). However, the role of kidneys in adiponectin biodegradation/elimination is unknown. Therefore, we assessed plasma adiponectin concentrations in ESRD patients before and after successful kidney transplantation.
  
  
  METHODS
  Among 44 hemodialyzed patients (29 men, 15 women; mean age 39 +/- 11 years; mean body mass index [BMI] 23.6 +/- 3.5 kg/m(2); mean duration of HD treatment before kidney transplantation 27 +/- 26 months), plasma adiponectin concentrations and insulin resistance indices (HOMA-R) were measured twice: immediately before kidney transplantation (Tx) and 1-2 days before patient discharge from the hospital with stable kidney transplant function (mean serum creatinine level 191 +/- 105 micromol/L). The control group consisted of 22 normotensive healthy subjects (12 men, 10 women).
  
  
  RESULTS
  Among uremic patients, before Tx, plasma adiponectin concentrations were significantly higher than in healthy subjects (20.8 +/- 8.3 vs 8.7 +/- 4.8 microg/mL; P <.001) After successful Tx, plasma adiponectin concentrations decreased significantly (20.8 +/- 8.3 vs 15.7 +/- 7.0 microg/mL before and after Tx, respectively; P <.001). Simultaneously, after successful kidney transplantation, an increase in HOMA-R was observed (1.01 +/- 0.61 vs 1.43 +/- 0.83; P =.002). However, changes in adiponectinemia did not significantly correlate with serum creatinine or HOMA-R.
  
  
  CONCLUSIONS
  The kidneys seem to play an important role in adiponectin biodegradation and/or elimination.
authors.affiliation: Department of Nephrology, Endocrinology, and Metabolic Diseases, Medical University of Silesia, Katowice, Poland.
authors.forename: J
authors.initials: J
authors.lastname: Chudek
authors.forename: M
authors.initials: M
authors.lastname: Adamczak
authors.forename: H
authors.initials: H
authors.lastname: Karkoszka
authors.forename: G
authors.initials: G
authors.lastname: Budziński
authors.forename: W
authors.initials: W
authors.lastname: Ignacy
authors.forename: T
authors.initials: T
authors.lastname: Funahashi
authors.forename: Y
authors.initials: Y
authors.lastname: Matsuzawa
authors.forename: L
authors.initials: L
authors.lastname: Cierpka
authors.forename: F
authors.initials: F
authors.lastname: Kokot
authors.forename: A
authors.initials: A
authors.lastname: Wiecek
mesh_terms: D052242:Adiponectin; D000328:Adult; D015415:Biomarkers / Q000097:blood*; D003404:Creatinine / Q000097:blood; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D036341:Intercellular Signaling Peptides and Proteins; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000601:surgery / Q000628:therapy; D016030:Kidney Transplantation / Q000276:immunology / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D011506:Proteins / Q000032:analysis*; D012016:Reference Values; D006435:Renal Dialysis; D014511:Uremia / Q000097:blood / Q000601:surgery
chemical_list: D052242:Adiponectin; D015415:Biomarkers; D007166:Immunosuppressive Agents; D036341:Intercellular Signaling Peptides and Proteins; D011506:Proteins; D003404:Creatinine